Phase II trial of weekly nab (nanoparticle albumin-bound)-paclitaxel (nab-paclitaxel) (Abraxane®) in combination with gemcitabine in patients with metastatic breast cancer (N0531)

Roy, Vivek; LaPlant, Betsy; Gross, Gerald G.; Bane, Charles L.; Palmieri, Frances M.

doi:10.1093/annonc/mdn661

Cited by 135 publications

(78 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…22 Several trials adding other drugs to nab-paclitaxel have been conducted to further improve the efficacy, such as carboplatin, gemcitabine, bevacizumab, and herceptin. [23][24][25] On the basis of our knowledge, this is also the first trial showing that the already-strong antitumor activity of weekly nab-paclitaxel for MBC can be further increased by adding a chemotherapeutic agent.…”

Section: Discussionmentioning

confidence: 87%

Cisplatin improves antitumor activity of weekly nab-paclitaxel in patients with metastatic breast cancer

Sun¹,

Tang²,

Zhang³

et al. 2014

IJN

View full text Add to dashboard Cite

Although nanoparticle albumin-bound paclitaxel (nab-paclitaxel) is approved to be given every 3 weeks, weekly use of this drug is becoming a new standard of care in patients with metastatic breast cancer (MBC). This prospective Phase II study was conducted to improve the efficacy of weekly nab-paclitaxel with cisplatin in MBC patients. Seventy-three women with recurrent or MBC were eligible for participation. Nab-paclitaxel was administered weekly at a dose of 125 mg/m 2 on day 1, day 8, and day 15, followed by cisplatin 75 mg/m 2 on day 1, repeated every 28 days with a maximum of 6 cycles. The primary objective was investigator-assessed overall response rate (ORR). A high ORR of 67.1% was obtained, with rates of 80.6% for the first-line patients and 80% for patients not pretreated with taxanes. Among those who had objective responses, a large percentage of patients (83.7%) showed quickly remarkable tumor shrinkage during the first two cycles. The median progression-free and overall survival times were 9.8 and 26.9 months, respectively. For the patients receiving first-, second-, and third-line therapy or beyond, median progression-free survival was 11.7, 7.7, and 7.6 months, respectively ( P =0.005). Molecular subtype was not significantly associated with ORR or disease progression. Grade 4 neutropenia occurred in 46 patients (63.0%), with febrile neutropenia found in 9 patients (12.3%). Grade 3 peripheral neuropathy was an accumulated dose-limiting toxicity occurring in 19 patients (26.0%). Efficacy of weekly nab-paclitaxel can be improved by adding cisplatin. The doublet is highly effective, with quick response, manageable toxicity, and possible equivalence across molecular subtypes in MBC patients.

show abstract

Section: Discussionmentioning

confidence: 87%

Cisplatin improves antitumor activity of weekly nab-paclitaxel in patients with metastatic breast cancer

Sun¹,

Tang²,

Zhang³

et al. 2014

IJN

View full text Add to dashboard Cite

show abstract

“…Based on the intention-totreat population, the reported orr was significantly increased with nab-paclitaxel than with standard Various phase ii studies have examined combinations of nab-paclitaxel with targeted agents-namely, trastuzumab and bevacizumab-for early treatment of mbc (orrs ranged from 30% to 60%) [62][63][64] . Studied chemotherapy combinations have included nabpaclitaxel with gemcitabine and with capecitabine (orrs ranged from 50% to 61%) 61,64,65 . Currently, nab-paclitaxel is being investigated in combination with targeted agents such as bevacizumab (search for NCT00618657 at http://clinicaltrials.gov/ct2/search).…”

Section: 31mentioning

confidence: 99%

Advances in the Management of Metastatic Breast Cancer: Options Beyond First-Line Chemotherapy

Ayoub

Verma

2012

Current Oncology

View full text Add to dashboard Cite

This article provides an overview of recent advances in chemotherapy that may be used for the treatment of patients with locally advanced or metastatic breast cancer (mbc). Key phase ii and iii trial data for eribulin mesylate, ixabepilone, and nab-paclitaxel, published since 2006, are discussed on the basis of recency, depth, and quality. Eribulin mesylate is the first monotherapy to significantly increase overall survival in patients with pretreated mbc, but nab-paclitaxel offers a novel and safer mode of delivery in comparison with standard taxanes. By contrast, the use of ixabepilone will be limited for now, until the associated neurotoxicity can be better managed. Alongside a brief overview of the other major chemotherapies currently in use, we have aimed to provide a Canadian context for how these novel agents may be integrated into clinical practice.

show abstract

“…Recently, a new generation of taxane based drugs have been developed and are known as nanoparticle albumin bound taxane (nab-paclitaxel) [25,26]. This modification was reported to exhibit less side effects than that normally produced from the use of taxane, and shows enhanced drug delivery into the targeted cancerous cells [25,27,28]. Nab-paclitaxel has been subjected to several phases of clinical trials.…”

Section: Introductionmentioning

confidence: 99%

Untitled

2017

MOJCSR

View full text Add to dashboard Cite

Breast cancer (BC) remains the most invasive diagnosed cancers among female, affecting 25% of total number of cancers worldwide. Systematic chemotherapies still remain one of the effective treatments for BC. One of the common and powerful chemotherapies that have been used in the past decade is taxane. Taxane are a class of anticancer compounds that are known to cause cell cycle arrest and apoptosis induction (cell death). They are used for the treatment of malignant tumors specifically BC along with other chemotherapies such as anthracycline. However, the neurotoxic effects that are associated with the use of taxane are still challenging. Recently, nanoparticle albumin bound taxane (nab-paclitaxel) was developed, resulting in lowering of the side effects that are associated with the use of taxane and enhancing its delivery to the targeted cancer cells. Nab-paclitaxel has been subjected to several clinical trials to evaluate its efficacy in the treatment of various types of cancers including BC. The results indicated that nab-paclitaxel showed an improved efficacy and promising outcomes in the treatment of various forms of BC. This review focuses on the comparison of classical taxane to the new generation, nab-paclitaxel chemotherapy, with emphasis on their comparative efficacy in metastatic BC (MBC) and triple negative metastatic BC (TNMBC) treatment, concluding that nab-paclitaxel has improved efficacy, safety data and with a more convenient administration confirming an optimal treatment option for patients in both cases. Future work is needed to optimize dosing schedules and combination regimens of nab-paclitaxel, which could broaden the clinical utility of this agent.

show abstract

Phase II trial of weekly nab (nanoparticle albumin-bound)-paclitaxel (nab-paclitaxel) (Abraxane®) in combination with gemcitabine in patients with metastatic breast cancer (N0531)

Cited by 135 publications

References 14 publications

Cisplatin improves antitumor activity of weekly nab-paclitaxel in patients with metastatic breast cancer

Cisplatin improves antitumor activity of weekly nab-paclitaxel in patients with metastatic breast cancer

Advances in the Management of Metastatic Breast Cancer: Options Beyond First-Line Chemotherapy

Untitled

Contact Info

Product

Resources

About